rs147244947

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BS1BS2

The NM_001429.4(EP300):​c.678C>G​(p.Gly226Gly) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00191 in 1,614,220 control chromosomes in the GnomAD database, including 31 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.0019 ( 2 hom., cov: 33)
Exomes 𝑓: 0.0019 ( 29 hom. )

Consequence

EP300
NM_001429.4 synonymous

Scores

2

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:5

Conservation

PhyloP100: 0.116

Publications

3 publications found
Variant links:
Genes affected
EP300 (HGNC:3373): (E1A binding protein p300) This gene encodes the adenovirus E1A-associated cellular p300 transcriptional co-activator protein. It functions as histone acetyltransferase that regulates transcription via chromatin remodeling and is important in the processes of cell proliferation and differentiation. It mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein. This gene has also been identified as a co-activator of HIF1A (hypoxia-inducible factor 1 alpha), and thus plays a role in the stimulation of hypoxia-induced genes such as VEGF. Defects in this gene are a cause of Rubinstein-Taybi syndrome and may also play a role in epithelial cancer. [provided by RefSeq, Jul 2008]
EP300 Gene-Disease associations (from GenCC):
  • Rubinstein-Taybi syndrome
    Inheritance: AD Classification: DEFINITIVE Submitted by: Illumina
  • Rubinstein-Taybi syndrome due to EP300 haploinsufficiency
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, G2P, Ambry Genetics
  • retinitis pigmentosa
    Inheritance: AD Classification: LIMITED Submitted by: G2P

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.54).
BP6
Variant 22-41117770-C-G is Benign according to our data. Variant chr22-41117770-C-G is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 341781.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=0.116 with no splicing effect.
BS1
Variant frequency is greater than expected in population eas. GnomAd4 allele frequency = 0.00194 (296/152344) while in subpopulation EAS AF = 0.0191 (99/5194). AF 95% confidence interval is 0.016. There are 2 homozygotes in GnomAd4. There are 167 alleles in the male GnomAd4 subpopulation. Median coverage is 33. This position passed quality control check.
BS2
High AC in GnomAd4 at 296 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
EP300NM_001429.4 linkc.678C>G p.Gly226Gly synonymous_variant Exon 2 of 31 ENST00000263253.9 NP_001420.2
EP300NM_001362843.2 linkc.678C>G p.Gly226Gly synonymous_variant Exon 2 of 30 NP_001349772.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
EP300ENST00000263253.9 linkc.678C>G p.Gly226Gly synonymous_variant Exon 2 of 31 1 NM_001429.4 ENSP00000263253.7

Frequencies

GnomAD3 genomes
AF:
0.00193
AC:
294
AN:
152226
Hom.:
2
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.000724
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00602
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.0192
Gnomad SAS
AF:
0.00352
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000705
Gnomad OTH
AF:
0.00335
GnomAD2 exomes
AF:
0.00258
AC:
648
AN:
251276
AF XY:
0.00262
show subpopulations
Gnomad AFR exome
AF:
0.000617
Gnomad AMR exome
AF:
0.00310
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.0135
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00110
Gnomad OTH exome
AF:
0.00391
GnomAD4 exome
AF:
0.00191
AC:
2787
AN:
1461876
Hom.:
29
Cov.:
32
AF XY:
0.00209
AC XY:
1519
AN XY:
727238
show subpopulations
African (AFR)
AF:
0.000777
AC:
26
AN:
33480
American (AMR)
AF:
0.00335
AC:
150
AN:
44722
Ashkenazi Jewish (ASJ)
AF:
0.0000383
AC:
1
AN:
26136
East Asian (EAS)
AF:
0.0319
AC:
1268
AN:
39700
South Asian (SAS)
AF:
0.00434
AC:
374
AN:
86256
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
53420
Middle Eastern (MID)
AF:
0.00625
AC:
36
AN:
5762
European-Non Finnish (NFE)
AF:
0.000722
AC:
803
AN:
1112006
Other (OTH)
AF:
0.00214
AC:
129
AN:
60394
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.486
Heterozygous variant carriers
0
200
401
601
802
1002
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
48
96
144
192
240
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00194
AC:
296
AN:
152344
Hom.:
2
Cov.:
33
AF XY:
0.00224
AC XY:
167
AN XY:
74512
show subpopulations
African (AFR)
AF:
0.000722
AC:
30
AN:
41576
American (AMR)
AF:
0.00621
AC:
95
AN:
15306
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3468
East Asian (EAS)
AF:
0.0191
AC:
99
AN:
5194
South Asian (SAS)
AF:
0.00352
AC:
17
AN:
4832
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10620
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.000706
AC:
48
AN:
68030
Other (OTH)
AF:
0.00331
AC:
7
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.491
Heterozygous variant carriers
0
15
29
44
58
73
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00167
Hom.:
0
Bravo
AF:
0.00235
Asia WGS
AF:
0.00779
AC:
27
AN:
3478
EpiCase
AF:
0.00125
EpiControl
AF:
0.00184

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:3
Jul 01, 2024
CeGaT Center for Human Genetics Tuebingen
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

EP300: BP4, BP7, BS1, BS2 -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Feb 09, 2021
GeneDx
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

EP300-related disorder Benign:1
May 02, 2019
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Rubinstein-Taybi syndrome due to EP300 haploinsufficiency Benign:1
Jan 24, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.54
CADD
Benign
9.5
DANN
Benign
0.66
PhyloP100
0.12
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.8
Mutation Taster
=100/0
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs147244947; hg19: chr22-41513774; COSMIC: COSV54327274; API